Cytonics Raises $794,000 to Fund Pre-Clinical Large Animal Studies for the Lead Recombinant Drug Candidate Cyt-108
Cytonics Has Expressed and Purified an Enzymatically Active Recombinant Alpha-2-Macroglobulin Variant (Cyt-108)
Cytonics Announces Issuance of PCT Patent for the APIC-PRP System and a Method of Producing Recombinant Alpha-2-Macroglobulin (A2M) Variants
Cytonics Announces Issuance of US Patent for the APIC-PRP System and a Method of Producing Recombinant Alpha-2-Macroglobulin (A2M) Variants
Cytonics Announces Issuance of US Patent for a Method of Treatment of Chronic Wounds Using Alpha-2-Macroglobulin (A2M) from Whole Blood or a Recombinant Variant of A2M
Cytonics Announces Issuance of UK Patent for an Alpha-2-Macroglobulin (A2M) Preparation from a Biological Sample
Cytonics Announces FDA Approval of an Investigational New Drug Application for the APIC Cell-Free System
Cytonics to Introduce the FACT™ Diagnostic for Joint and Spine Related Pain at the 2013 Workers Compensation Conference in Orlando, FL
Cytonics Receives Notice of Allowance for Patent Related to FACT™ Diagnostic for Back and Joint Pain
Peer Reviewed Publications
Reserve Shares Today!
Be part of the relief for OA
Cytonics has received over $15M in funding to-date, including $1.8M in grants from the National Institute of Health and a $4M investment from Synthes (a Johnson and Johnson company). We are seeking to raise $19M by conducting a public offering under Regulation A. Proceeds will be used to advance our lead drug candidate, Cyt-108, into FDA clinical trials and fund ongoing business operations.
Cytonics Corporation is offering securities under Regulation A through SI Securities, LLC (“SI Securities”). The Company has filed a Form C with the Securities and Exchange Commission in connection with its offering, a copy of which may be obtained at: https://seedinvest.com/cytonics